Skip to main content

Statins

11-07-2022 | Lipid-lowering medications | News

Pemafibrate disappoints in high-risk type 2 diabetes

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

03-29-2022 | Cardiovascular disorders | News

Best statins for non-HDL cholesterol reduction in diabetes revealed

Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.

10-26-2021 | Statins | News

Statin treatment linked to increased likelihood of diabetes progression

Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.

Statin medication packet

07-12-2021 | Ethnic groups | News

High CVD cost of ethnic statin prescribing disparities in type 2 diabetes

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

06-29-2021 | ADA 2021 | Conference coverage | News

Statin duration may be crucial determinant of type 2 diabetes MACE risk

The duration of statin therapy in people with type 2 diabetes may be even more important than the intensity or the achieved level of low-density lipoprotein cholesterol for preventing cardiovascular events, research suggests.

08-07-2020 | Adverse effects | News

Case of canagliflozin-triggered rosuvastatin-induced myotoxicity reported

Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.

01-30-2019 | Retinopathy | News

Possible retinopathy benefits with statins for diabetes patients with dyslipidemia

A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.

06-05-2017 | Statins | News

Keeping fit could ward off statin-related diabetes risk

Researchers find that the increased risk for type 2 diabetes among patients taking statins is limited to the least fit individuals.